Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Keating

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Eye & Contact Lens|August 31, 2011
Trichosporon asahii keratitis in a patient with a type I Boston keratoprosthesis and contact lensAnne Keating, Roberto Pineda
Seminars in Ophthalmology|November 25, 2010
Corneal cross linking for keratoconusAnne Keating, Roberto Pineda, Kathryn Colby
International Journal for Parasitology|July 16, 2002
Diplostomum spathaceum cercariae respond to a unique profile of cues during recognition of their fish hostWilfried Haas, Petra Stiegeler, Anne Keating, et al.
Breast Cancer Research and Treatment|December 31, 2014
Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancerMichael R Clemens, Oleg A Gladkov, Elaina Gartner, et al.
Leukemia & Lymphoma|February 10, 2016
A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphomaKyriakos P Papadopoulos, Javier Lopez-Jimenez, Scott E Smith, et al.
Cancer Medicine|December 24, 2014
A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanomaRagini Kudchadkar, Scott Ernst, Bartosz Chmielowski, et al.
Blood|January 17, 2013
Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemiaJing Chen, Cynthia A Pise-Masison, Joanna H Shih, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2016
BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal CancerAl B Benson, Igor Kiss, John Bridgewater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2008
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivinAnthony W Tolcher, Alain Mita, Lionel D Lewis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2017
A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor MutationsHelena A Yu, Alexander Spira, Leora Horn, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Eye & Contact Lens|August 31, 2011
Trichosporon asahii keratitis in a patient with a type I Boston keratoprosthesis and contact lensAnne Keating, Roberto Pineda
Seminars in Ophthalmology|November 25, 2010
Corneal cross linking for keratoconusAnne Keating, Roberto Pineda, Kathryn Colby
International Journal for Parasitology|July 16, 2002
Diplostomum spathaceum cercariae respond to a unique profile of cues during recognition of their fish hostWilfried Haas, Petra Stiegeler, Anne Keating, et al.
Breast Cancer Research and Treatment|December 31, 2014
Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancerMichael R Clemens, Oleg A Gladkov, Elaina Gartner, et al.
Leukemia & Lymphoma|February 10, 2016
A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphomaKyriakos P Papadopoulos, Javier Lopez-Jimenez, Scott E Smith, et al.
Cancer Medicine|December 24, 2014
A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanomaRagini Kudchadkar, Scott Ernst, Bartosz Chmielowski, et al.
Blood|January 17, 2013
Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemiaJing Chen, Cynthia A Pise-Masison, Joanna H Shih, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2016
BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal CancerAl B Benson, Igor Kiss, John Bridgewater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2008
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivinAnthony W Tolcher, Alain Mita, Lionel D Lewis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2017
A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor MutationsHelena A Yu, Alexander Spira, Leora Horn, et al.
Pageof 1